Trimetazidine in conditions other than coronary disease, old drug, new tricks?

Abstract Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2017-05, Vol.234, p.1-6
Main Authors: Zou, Hai, Zhu, Xing-Xing, Ding, Ya-Hui, Jin, Qin-Yang, Qian, Lin-Yan, Huang, Dong-Sheng, Cen, Xue-Jiang
Format: Article
Language:English
Subjects:
Acetyl-CoA C-Acyltransferase - metabolism
Antineoplastic Agents - adverse effects
Cardiovascular
Chemically-Induced Disorders - drug therapy
Chemically-Induced Disorders - etiology
Contrast-induced nephropathy
Coronary Artery Disease - drug therapy
Coronary Artery Disease - metabolism
Diabetic Cardiomyopathies - drug therapy
Diabetic cardiomyopathy
Drug Repositioning
Humans
Kidney Diseases - chemically induced
Kidney Diseases - drug therapy
Mitochondria, Heart - metabolism
Myocardial dysfunction induced by anti-cancer drugs
Non-ischemic cardiomyopathy
Sepsis
Trimetazidine
Trimetazidine - pharmacology
Vasodilator Agents - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2017.02.083